
Contributions
Abstract: P776
Type: Poster
Abstract Category: Therapy - symptomatic - Quality of life
Introduction: Multiple Sclerosis (MS) is a chronic inflammatory and degenerative neurological disease, causing walking disability in up to 70% of subjects affected with the disease. Quality of life (QoL) is an important aspect of MS closely related to walking capability.
Fampridine is the first medication approved for improving walking disability in MS, but its impact on QoL has not been explored in a long term follow-up.
Objective: To analyze QoL in subjects with MS responding to fampridine in a period over two years.
Methods: QoL was monitored with the EQ-5D questionnaire, the Würzburger fatigue inventory for MS (WEIMuS) and the Common Depression scale (ADS-L), which were applied before starting treatment with fampridine, two weeks after beginning of treatment, and once annually. Gait assessment was performed by Timed-25 Foot Walk Test (T25FW).
Results: 134 subjects with diagnosis of MS and responding to Fampridine were included, of which 87 were female (65.4%) and 46 (34.6%) were male, their mean age was 54.3 (SD± 11.4), mean EDSS was 5.2 (SD ± 1.3); 55 (42%) had a diagnosis of Relapsing-remitting MS, 40 (30.5%) had secondary progressive MS, and 36 (27.5%) had primary progressive MS. Their mean disease evolution time in years since diagnosis was 13.5 (SD ±8.4).
All subjects had a mean significant improvement in the EQ-5D, ADS-L and WEIMuS from baseline to two weeks (p< .05) afterwards [EQ-5D= 5.4 (SD±1.9) and 6.31 (SD+1.7); ADS-L= 14.8 (SD±8.3) and 12.6 (SD±7.3); WEIMuS= 16.5 (SD±7.1) and 12.9 (SD± 7.2), at baseline and two weeks later, respectively], and a non-significant improvement one year and two years after the beginning of treatment, as compared to baseline. Compared to the two week time point, a non-significant decrease [EQ-5D= 5.6 (SD± 2.04) and 5.5 (SD± 2.0); ADS-L= 15.1 (SD±9.5) and= 14.6 (SD± 7.4); WEIMuS= 15.3
(SD ± 7.2) and 15.3 (SD ± 6.8) ] was observed one year and two years after baseline, respectively.
In gait analysis, there was a significant speed improvement in the T25FW from a mean baseline time of 16.4 (SD 27.2) to 12.3 (SD 17.2) after two weeks (p= .05), but not a sustained speed improvement after one and two years.
Conclusion: QoL in subjects with MS responding to Fampridine is affected in a similar fashion as walking speed in the long term follow up which is probably part of the ongoing clinical process. Further functional outcomes and their relationship to the effects of fampridine must be explored in the future.
Disclosure:
Francisco Rodriguez-Leal: Nothing to disclose
Judith Eisele: nothing to disclose
Undine Heinke: Nothing to disclose
Urszula Konofalska: Nothing to disclose
Katja Thomas: received speaker honoraria from Novartis, Bayer, Biogen Idec; J.
Schultheiss T: Nothing to disclose
Tjalf Ziemssen: is on the scientific advisory board for Bayer Healthcare, Biogen Idec, Genzyme, MSD, GDSK, Novartis, Teva, Sanofi, Almirall, is section editor for BMC Neurology, received research support from Bayer Healthcare, Biogen Idec, Genzyme, Novartis, Teva, Sanofi.
Abstract: P776
Type: Poster
Abstract Category: Therapy - symptomatic - Quality of life
Introduction: Multiple Sclerosis (MS) is a chronic inflammatory and degenerative neurological disease, causing walking disability in up to 70% of subjects affected with the disease. Quality of life (QoL) is an important aspect of MS closely related to walking capability.
Fampridine is the first medication approved for improving walking disability in MS, but its impact on QoL has not been explored in a long term follow-up.
Objective: To analyze QoL in subjects with MS responding to fampridine in a period over two years.
Methods: QoL was monitored with the EQ-5D questionnaire, the Würzburger fatigue inventory for MS (WEIMuS) and the Common Depression scale (ADS-L), which were applied before starting treatment with fampridine, two weeks after beginning of treatment, and once annually. Gait assessment was performed by Timed-25 Foot Walk Test (T25FW).
Results: 134 subjects with diagnosis of MS and responding to Fampridine were included, of which 87 were female (65.4%) and 46 (34.6%) were male, their mean age was 54.3 (SD± 11.4), mean EDSS was 5.2 (SD ± 1.3); 55 (42%) had a diagnosis of Relapsing-remitting MS, 40 (30.5%) had secondary progressive MS, and 36 (27.5%) had primary progressive MS. Their mean disease evolution time in years since diagnosis was 13.5 (SD ±8.4).
All subjects had a mean significant improvement in the EQ-5D, ADS-L and WEIMuS from baseline to two weeks (p< .05) afterwards [EQ-5D= 5.4 (SD±1.9) and 6.31 (SD+1.7); ADS-L= 14.8 (SD±8.3) and 12.6 (SD±7.3); WEIMuS= 16.5 (SD±7.1) and 12.9 (SD± 7.2), at baseline and two weeks later, respectively], and a non-significant improvement one year and two years after the beginning of treatment, as compared to baseline. Compared to the two week time point, a non-significant decrease [EQ-5D= 5.6 (SD± 2.04) and 5.5 (SD± 2.0); ADS-L= 15.1 (SD±9.5) and= 14.6 (SD± 7.4); WEIMuS= 15.3
(SD ± 7.2) and 15.3 (SD ± 6.8) ] was observed one year and two years after baseline, respectively.
In gait analysis, there was a significant speed improvement in the T25FW from a mean baseline time of 16.4 (SD 27.2) to 12.3 (SD 17.2) after two weeks (p= .05), but not a sustained speed improvement after one and two years.
Conclusion: QoL in subjects with MS responding to Fampridine is affected in a similar fashion as walking speed in the long term follow up which is probably part of the ongoing clinical process. Further functional outcomes and their relationship to the effects of fampridine must be explored in the future.
Disclosure:
Francisco Rodriguez-Leal: Nothing to disclose
Judith Eisele: nothing to disclose
Undine Heinke: Nothing to disclose
Urszula Konofalska: Nothing to disclose
Katja Thomas: received speaker honoraria from Novartis, Bayer, Biogen Idec; J.
Schultheiss T: Nothing to disclose
Tjalf Ziemssen: is on the scientific advisory board for Bayer Healthcare, Biogen Idec, Genzyme, MSD, GDSK, Novartis, Teva, Sanofi, Almirall, is section editor for BMC Neurology, received research support from Bayer Healthcare, Biogen Idec, Genzyme, Novartis, Teva, Sanofi.